COCRYSTAL PHARMA INC (COCP)

US19188J4094 - Common Stock

1.605  +0.03 (+2.23%)

Fundamental Rating

3

Taking everything into account, COCP scores 3 out of 10 in our fundamental rating. COCP was compared to 198 industry peers in the Pharmaceuticals industry. COCP has a great financial health rating, but its profitability evaluates not so good. COCP does not seem to be growing, but still is valued expensively.



1

1. Profitability

1.1 Basic Checks

COCP had negative earnings in the past year.
In the past year COCP has reported a negative cash flow from operations.
In the past 5 years COCP always reported negative net income.
COCP had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -57.56%, COCP is in line with its industry, outperforming 40.51% of the companies in the same industry.
The Return On Equity of COCP (-68.20%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -57.56%
ROE -68.2%
ROIC N/A
ROA(3y)-56.87%
ROA(5y)-71.48%
ROE(3y)-61.52%
ROE(5y)-78.07%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

COCP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

7

2. Health

2.1 Basic Checks

The number of shares outstanding for COCP has been increased compared to 1 year ago.
Compared to 5 years ago, COCP has more shares outstanding
COCP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -13.43, we must say that COCP is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -13.43, COCP is not doing good in the industry: 81.03% of the companies in the same industry are doing better.
COCP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.43
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 8.92 indicates that COCP has no problem at all paying its short term obligations.
The Current ratio of COCP (8.92) is better than 83.59% of its industry peers.
COCP has a Quick Ratio of 8.92. This indicates that COCP is financially healthy and has no problem in meeting its short term obligations.
COCP has a Quick ratio of 8.92. This is amongst the best in the industry. COCP outperforms 84.10% of its industry peers.
Industry RankSector Rank
Current Ratio 8.92
Quick Ratio 8.92

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 59.83% over the past year.
EPS 1Y (TTM)59.83%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q20%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, COCP will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.04% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-17.03%
EPS Next 2Y10.04%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

COCP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year COCP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.04%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for COCP!.
Industry RankSector Rank
Dividend Yield N/A

COCRYSTAL PHARMA INC

NASDAQ:COCP (5/8/2024, 3:30:01 PM)

1.605

+0.03 (+2.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap16.32M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -57.56%
ROE -68.2%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 8.92
Quick Ratio 8.92
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)59.83%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-17.03%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y